Summary of Embecta (EMBC) FY Conference Call - June 10, 2025 Company Overview - **Company**: Embecta (formerly part of Becton Dickinson's diabetes care business) - **Revenue**: Approximately $1.1 billion - **Product Categories**: - Pen needles - Conventional syringes - Safety products for injections - **Geographic Revenue Distribution**: - 50% from the US - ~30% from Europe, Middle East, and Africa - ~20% from Asia Pacific (including China) - ~5% from Latin America - **Business Model**: Focused on single-use disposable products for diabetes management, with a stable and recurring revenue base [4][5][6] Financial Performance and Projections - **Historical Performance**: - Revenue growth from 2022 to 2024 was around 1.3% CAGR, exceeding initial expectations of flat growth [11] - Adjusted EBITDA margins improved to 31.4%, surpassing the target of 30% despite facing inflationary pressures [13] - **Future Projections (2025-2028)**: - Expected constant currency revenue CAGR remains flattish, with a target of low single-digit growth [15] - Projected cumulative free cash flow of at least $600 million from 2026 to 2028, with plans to reduce debt by $450 million to $500 million during this period [15][49] - **Challenges**: - Decline in conventional syringe business in the US, projected to drop from $90 million in 2019 to around $35 million by 2025 [18] - Impact of pharmacy closures affecting inventory purchases and revenue [38] Growth Opportunities - **GLP-1 Market**: - Identified as the single biggest growth opportunity, with expectations for multi-dose pen injectors to replace single-use auto injectors [30][31] - Anticipated market opportunity of at least $100 million by 2033, with potential revenue contributions starting as early as 2026 [32][33] - **New Product Revenue Streams**: - Entering distribution agreements for products like blood glucose monitors and insulin pumps to diversify offerings [35] Operational Insights - **Manufacturing and Supply Chain**: - Transitioning to a new ERP system and establishing independent distribution networks post-spin from Becton Dickinson [8][9] - Current gross margins around 63%, with expectations for slight declines due to tariffs and increased R&D expenses [40][41] - **Debt Management**: - Current net leverage at 3.7 times, with a goal to reduce it to around 2 times by 2028 [48][49] Market Dynamics - **Geographic Growth**: - Emerging markets expected to grow at mid-single digits, while US business projected to see low single-digit declines [26][27] - **Impact of Formulary Changes**: - Generally viewed as beneficial if they make insulin more affordable for patients [25] Conclusion - **Investor Sentiment**: - Positive reception post-Analyst Day, with a focus on cautious and achievable financial projections [54][55] - **Future Outlook**: - The company aims to leverage its free cash flow capabilities to enhance its product portfolio and maintain stable growth despite market challenges [10][55]

Embecta (EMBC) 2025 Conference June 05, 2025 04:55 PM ET Speaker0 All right. Good afternoon, everyone. My name is Mike Sarcone. I'm an analyst on the US medical supplies and devices team here. And this is the last session for Jefferies twenty twenty five New York Healthcare Conference and this is a fireside chat with MBECTA. And from the company we've got Jake Elgouy, CFO and we're also joined here by Pravesh Kandawal who heads the IR function. So gentlemen, thank you both for being with us today. Speaker1 ...

Embecta (EMBC) 2025 Investor Day May 22, 2025 09:00 AM ET Speaker0 Good morning, everyone, and welcome to Ambecta's first ever analyst and investor day. My name is Pravesh Khandilwal, and I'm the vice president of investor relations. The slides that accompanies today's event and webcast replay details are available on the investor relations section of our website at www.mbecta.com. Before we begin, I would like to remind you that some of the matters discussed in the event will contain forward looking statem ...

Embecta (EMBC) Q2 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants Devdatt Kurdikar - President & CEOJake Elguicze - Senior VP & CFOMarie Thibault - Managing DirectorAnthony Petrone - Managing Director Equity Research Conference Call Participants Kallum Titchmarsh - AnalystMichael Polark - Senior Equity Research Analyst Devdatt Kurdikar And long term success. Turning to some fiscal second quarter highlights. Second quarter revenue totaled $259,000,000 which exceeded our expectations of betwe ...

Embecta (EMBC) Q2 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants Devdatt Kurdikar - President & CEOJake Elguicze - Senior VP & CFOMarie Thibault - Managing DirectorAnthony Petrone - Managing Director Equity Research Conference Call Participants Kallum Titchmarsh - AnalystMichael Polark - Senior Equity Research Analyst Devdatt Kurdikar And long term success. Turning to some fiscal second quarter highlights. Second quarter revenue totaled $259,000,000 which exceeded our expectations of betwe ...

Embecta (EMBC) Q2 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 And long term success. Turning to some fiscal second quarter highlights. Second quarter revenue totaled $259,000,000 which exceeded our expectations of between $250,000,000 and $255,000,000 that we provided on our last earnings call. As compared to the midpoint of our prior guidance range, approximately half of the overachievement in the quarter was due to constant currency performance, while the other half was due to foreign exchange be ...

Earnings Conference Call Q2 Fiscal Year 2025 May 9, 2025 Safe Harbor Statement Regarding Forward-Looking Statements This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding our future results from operations, performance, financial condition, goals, strategies, plans, achievements, and anticipated product clea ...

PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter’s financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flex ...